Tandem Diabetes Care (TNDM) Research & Development (2013 - 2026)

Tandem Diabetes Care has reported Research & Development for 14 years, with the latest figure at $46.0 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 8.32% year-over-year to $46.0 million; the trailing twelve-month figure through Mar 2026 stood at $188.9 million (down 6.86% YoY), and the FY2025 full-year result was $193.1 million, down 2.9% from the prior year.
• Research & Development for Q1 2026 stood at $46.0 million, roughly flat from $46.1 million in the prior quarter.
• The five-year high for Research & Development was $52.2 million in Q4 2024, with the low at $33.2 million in Q1 2022.
• Historically, Research & Development has averaged $43.9 million across 5 years, with a median of $46.0 million in 2026.
• Annual changes were most pronounced in 2022 — Research & Development jumped 84.62% — and 2025, when it fell 11.75%.
• Tandem Diabetes Care's Research & Development stood at $35.6 million in 2022, then increased by 19.72% to $42.6 million in 2023, then climbed by 22.52% to $52.2 million in 2024, then slipped by 11.75% to $46.1 million in 2025, then slipped by 0.07% to $46.0 million in 2026.
• The last three Research & Development figures came in at $46.0 million (Q1 2026), $46.1 million (Q4 2025), and $48.7 million (Q3 2025), per Business Quant data.